Re: Das et al.: Diabetic macular edema: pathophysiology and novel therapeutic targets (Ophthalmology 2015;122:1375-94)

I read “Diabetic macular edema: pathophysiology and novel therapeutic targets” published July 2015 by Das et al. This article is interesting because it outlines the role that inflammation plays in the pathogenesis of diabetic macular edema (DME) and discusses the novel therapies in this disease area. Das et al refer to the efficacy and safety of the fluocinolone acetonide (FAc) implant (ILUVIEN), which is licensed for the treatment of DME in a number of European countries and the United States. However, the authors do not present the data relating to ILUVIEN specifically (with a release rate of 0.2 μg FAc per day1), nor do they outline the differences between licensed indications in Europe and the United States.